Date: 2014-07-24
Type of information: Financing round
Company: Atox Bio (Israel)
Investors: SR One (UK) Lundbeckfond Ventures (Denamrk) OrbiMed Israel (Israel)
Amount: $23 Million
Funding type: Series E financing round
Planned used: The funds will enable Atox Bio to initiate a late stage clinical study of AB103, a novel therapy for the treatment of Necrotizing Soft Tissue Infections, commonly referred to as the “flesh eating bacteria” and other severe infections. The study is expected to start in the second half of 2015. AB103, a novel immunomodulator discovered by Prof. Raymond Kaempfer and Dr. Gila Arad and licensed from Yissum, the technology transfer company of the Hebrew University, is a rationally designed, short peptide that modulates the host’s inflammatory response through binding to the CD28 dimer interface. AB103 successfully completed a Phase 2 study in patients with NSTI. The results demonstrated that patients treated with AB103 had a meaningful improvement across multiple end points. Patients treated with AB103 had a faster resolution of organ dysfunction, spent fewer days in the intensive care unit, required fewer days of assisted ventilation and needed fewer surgical procedures to remove infected tissue.
Others: * On July 24, 2014, Atox Bio, developer of therapeutics for severe infections, announced that it has raised up to $23 million in a Series E investment led by SR One with participation by Lundbeckfond Ventures and OrbiMed Israel.
Therapeutic area: Infectious diseases
